Clinical trials: Attention Deficit Disorders With Hyperactivity
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder
GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs
The purpose of this study is to examine the use of, and reaction to, one particular software application(GroundsKeeper) delivered on unique platform - Sifteo cubes (www.sifteo.com).
- Conditions
- Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Pervasive Developmental Disorder, Asperger's Disorder
- Trial name
- NCT01808066
- Testing
- Groundskeeper
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- CogCubed, Corp
ADHD
The Reinforcing Mechanisms of Smoking in Adult ADHD
Whereas the smoking prevalence rates in the general population are declining, rates among people diagnosed with attention-deficit hyperactivity disorder (ADHD) continue to be elevated.
- Trial name
- NCT00573859
- Testing
- ADHD medication
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Irvine
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
This study evaluates the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT03605680
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 604 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention-Deficit/Hyperactivity Disorder
Communication to Improve Shared Decision-Making in ADHD
The purpose of this study was to explore whether using an online patient portal plus a Care Manager is more effective than using an online portal alone in managing care for children with ADHD.
- Trial name
- ADHD-Link (NCT02716324)
- Testing
- Care Manager CM), ADHD Portal
- Where
- United States
- Volunteers
- 303 people
- Sponsor
- Children's Hospital of Philadelphia
Attention Deficit Hyperactivity Disorder
A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
LYDO is a multi-center study that will enroll approximately 1925 adult outpatients with Attention Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT00700427
- Testing
- atomoxetine hydrochloride
- Where
- 56 sites in Austria, Belgium and 10 more
- Volunteers
- 2,017 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents
The main purpose of the study is to help to understand the effect on children and adolescents who are stable on treatment with atomoxetine or osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity…
- Trial name
- EMD (NCT01127646)
- Testing
- Atomoxetine, Osmotic-release oral system methylphenidate
- Where
- 14 sites in Netherlands, Spain and 1 more
- Volunteers
- 23 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
Omega-3 Supplementation to ADHD Medication in Children
This study is a 12-week open-label trial to assess the effectiveness of Omega-3 fatty acids for deficient emotional self-regulation (DESR) as a supplement to Attention Deficit/Hyperactivity Disorder (ADHD) treatment in children…
- Trial name
- NCT02204410
- Testing
- Omega-3 Fatty Acid, ADHD Medication
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
ADHD
Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate efficacy, safety and tolerability of metadoxine (MG01CI) extended release formulation for the treatment of adults diagnosed with ADHD
- Trial name
- NCT01243242
- Testing
- Metadoxine (MG01CI)
- Where
- 2 sites in Israel
- Volunteers
- 120 people
- Sponsor
- Alcobra Ltd.
Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder
Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia
This study seeks to determine, using special sleep tests (polysomnography and actigraphy) if guanfacine extended release is able to improve nighttime sleep in children with ADHD - associated insomnia while improving daytime ADHD…
- Conditions
- Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders
- Trial name
- NCT01156051
- Testing
- Guanfacine extended-release tablets
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Children's Specialized Hospital
TBI, Attention Deficits
Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors
The overall goal of the proposed project is to perform a preliminary study to assess the potential effects of galvanic vestibular stimulation (GVS) on the outcomes of a cognitive test of attention and the outcomes of…
- Conditions
- TBI, Attention Deficits, Motor Impairments
- Trial name
- NCT01749800
- Testing
- GVS, Armeo Spring
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Spaulding Rehabilitation Hospital
ADHD
Motivated Behavior in Adults With and Without ADHD
To investigate the effects of methylphenidate on motivated behavior in adults with and without ADHD
- Trial name
- MOBE (NCT02630017)
- Where
- 2 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Attention-Deficit/Hyperactivity Disorder
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)
The primary purpose is to assess the efficacy of once daily dosing with optimized SPD503 (1, 2, 3 and 4mg/day), dosed either in the morning or evening, compared to placebo, in children with ADHD as measured by change from…
- Trial name
- NCT00997984
- Testing
- extended-release guanfacine hydrochloride (SPD503), extended-release guanfacine hydrochloride
- Where
- 46 sites in United States, Canada
- Volunteers
- 340 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
The purpose of this study was to evaluate the effect of SPN-810 for the treatment of impulsive aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard ADHD treatment.
- Trial name
- NCT03597503
- Testing
- SPN-810
- Where
- 38 sites in United States
- Volunteers
- 41 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit/Hyperactivity Disorder
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder
- Trial name
- NCT01338818
- Testing
- Ritalin LA (methylphenidate hydrochloride extended release)
- Where
- 48 sites in United States, Belgium and 4 more
- Volunteers
- 299 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit Hyperactivity Disorder
A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
The purpose of this study is to determine whether PF-03654746 is effective in the treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00531752
- Testing
- PF-03654746
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder (ADHD)
Integrated Brain, Body and Social Intervention for Attention Deficit Hyperactivity Disorder (ADHD)
The investigators are conducting this randomized trial to determine if IBBS (Integrated Brain, Body, and Social)intervention is an effective treatment for ADHD (attention Deficit Hyperactivity Disorder) in two culturally distinct…
- Trial name
- IBBS (NCT01542528)
- Testing
- IBBS
- Where
- 5 sites in United States, China
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Yale University
ADHD
KP415 Classroom Study in Children (6-12 Years of Age) With ADHD
The study is a multicenter, dose-optimized, double-blind, randomized, placebo-controlled, parallel efficacy laboratory classroom study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03292952
- Testing
- KP415 oral capsule
- Where
- 5 sites in United States
- Volunteers
- 155 people
- Sponsor
- Zevra Therapeutics
Attention Deficit Hyperactivity Disorder
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages…
- Trial name
- NCT00904670
- Testing
- Quillivant Oral Suspension XR
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder
Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)
This is a Phase 2 multicenter, randomized, double-blind trial of MK-8777 (Org 26576, SCH 900777) in adult subjects with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT00610441
- Testing
- MK-8777
- Volunteers
- 67 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
The purpose of this study is to a) assess the efficacy of omega-3 fatty acids in the treatment of Deficient Emotional Self-Regulation (DESR) among stimulant treated Attention Deficit Hyperactivity Disorder (ADHD) adults, b)…
- Trial name
- NCT01399827
- Testing
- ADHD Medication, Omega-3 Fatty Acids
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital